Trials / Completed
CompletedNCT00216398
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy, safety and patient acceptability of Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanreotide (Autogel formulation) |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-06-22
- Completion
- 2006-06-22
- First posted
- 2005-09-22
- Last updated
- 2019-08-16
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00216398. Inclusion in this directory is not an endorsement.